The stock price performance for the year has been a mixed bag, indicating either a pessimistic or optimistic outlook depending on how you look at it. Year to date metric has recorded a loss of -29.78%.However, over the last six months, we can see a stronger performance of -16.67%. Over the last 30 days, the price of PLX has leaped by -0.79%. And in the last five days, it has surged by 7.76%.
Protalix BioTherapeutics Inc. experienced a rather shaky stock market performance. The highest value in the past year was recorded at $3.13 on 05/10/23 and the lowest value was $1.07 on 05/06/24.
52-week price history of PLX Stock
Analyzing a stock’s 52-week high and low prices can offer important information about its present condition and future outlook. Protalix BioTherapeutics Inc.’s current trading price is -60.06% away from its 52-week high, while its distance from the 52-week low is 16.82%. The stock’s price range during this period has varied between$1.07 and $3.13. The Protalix BioTherapeutics Inc.’s shares, which operate in the Healthcare, saw a trading volume of around 0.79 million for the day, a figure considerably higher than their average daily volume of 0.39 million over last three months.
Market Capitalization vs. Financial Performance: A Comparative Study
Protalix BioTherapeutics Inc. (PLX) has experienced a quarterly decline of -16.67% in its revenues when compared to the same period in the previous year. Presently, the company has a total market capitalization of 91.65M and boasts a workforce of 208 employees.
Combining Moving Average and Trading Volume Data for Better Market Insight
Based on Barchart.com data, the company’s moving average over the 100-day period was 1.4330, with a change in price of -0.5100. Similarly, Protalix BioTherapeutics Inc. recorded 357,574 in trading volume during the last 100 days, posting a change of -28.98%.
PLX’s Debt-to-Equity Ratio Cause for Concern? An In-Depth Look
The debt-to-equity (D/E) ratio is a significant metric that provides insights into a company’s financial state and market presence. By dividing a company’s current liabilities by its shareholders’ equity, the D/E ratio depicts the extent of debt used by a company to fund its assets relative to the value of its shareholders’ equity. At the time of writing, the total D/E ratio for PLX stands at 0.78. Similarly, the long-term debt-to-equity ratio is also 0.14.
PLX Stock Stochastic Average
Protalix BioTherapeutics Inc.’s raw stochastic average for the past 50 days is presently 29.51%, as of today. This marks a decrease from the raw stochastic average of the last 20 days, which was 100.00%. Additionally, the company’s Stochastic %K and %D values for the past 20 days were 53.42% and 32.80%, respectively.
